NasdaqCM - Delayed Quote USD

Theratechnologies Inc. (THTX)

1.3000 -0.1100 (-7.80%)
At close: April 25 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Paul Lévesque President, CEO & Director 1.18M -- 1964
Mr. Philippe Dubuc M.B.A., MBA Senior VP & CFO 432.31k -- 1967
Mr. Jocelyn Lafond L.L.M., LL.B. General Counsel & Corporate Secretary 316.29k -- 1968
Dr. Christian Marsolais Ph.D. Senior VP & Chief Medical Officer 434.61k -- 1963
Mr. John Leasure Global Commercial Officer 420.91k -- 1965
Hon. Andre Dupras M.Sc. Vice President of Human Resources -- -- 1964

Theratechnologies Inc.

2015 Peel Street
11th Floor
Montreal, QC H3A 1T8
Canada
514 336 7800 https://www.theratech.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
103

Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Corporate Governance

Theratechnologies Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 9; Board: 2; Shareholder Rights: 7; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Jul 10, 2024 - Jul 15, 2024
Theratechnologies Inc. Earnings Call

Related Tickers

ATBPF Antibe Therapeutics Inc.
0.2156
0.00%
 
IGX.TO IntelGenx Technologies Corp.
0.1850
-7.50%
 
DVHGF Devonian Health Group Inc.
0.1689
0.00%
 
SRBCF Sirona Biochem Corp.
0.0520
+25.00%
 
KNBIF Kane Biotech Inc.
0.0898
0.00%
 
SIGY Sigyn Therapeutics, Inc.
5.75
0.00%
 
EVG.L Evgen Pharma plc
0.8000
0.00%
 
IVBXF Innovent Biologics, Inc.
4.8900
0.00%
 
KNE.V Kane Biotech Inc.
0.1300
+4.00%
 
HBP.TO Helix BioPharma Corp.
0.2100
+7.69%